Interleukin-6 As a Director of Immunological Events and Tissue Regenerative Capacity in Hemodialyzed Diabetes Patients

Overview

Journal Med Sci (Basel)

Specialty General Medicine

Date 2024 Jun 26

PMID 38921685

Authors

Maria-Florina Trandafir

Octavian Savu

Daniela Pasarica

Coralia Bleotu

Mihaela Gheorghiu

Affiliations

Soon will be listed here.

Abstract

Hemodialyzed patients have innate immunity activation and adaptive immunity senescence. Diabetes mellitus is a frequent cause for chronic kidney disease and systemic inflammation. We studied the immunological pattern (innate and acquired immunity) and the tissular regeneration capacity in two groups of hemodialyzed patients: one comprised of diabetics and the other of non-diabetics. For inflammation, the following serum markers were determined: interleukin 6 (IL-6), interleukin 1β (IL-1β), tumoral necrosis factor α (TNF-α), IL-6 soluble receptor (sIL-6R), NGAL (human neutrophil gelatinase-associated lipocalin), and interleukin 10 (IL-10). Serum tumoral necrosis factor β (TNF-β) was determined as a cellular immune response marker. Tissue regeneration capacity was studied using neurotrophin-3 (NT-3) and vascular endothelial growth factor β (VEGF-β) serum levels. The results showed important IL-6 and sIL-6R increases in both groups, especially in the diabetic patient group. IL-6 generates trans-signaling at the cellular level through sIL-6R, with proinflammatory and anti-regenerative effects, confirmed through a significant reduction in NT-3 and VEGF-β. Our results suggest that the high serum level of IL-6 significantly influences IL-1β, TNF-β, NT-3, VEGF-β, and IL-10 behavior. Our study is the first that we know of that investigates NT-3 in this patient category. Moreover, we investigated VEGF-β and TNF-β serum behavior, whereas most of the existing data cover only VEGF-α and TNF-α in hemodialyzed patients.

References

Malik A, Baldwin M, Peale F, Fuh G, Liang W, Lowman H . Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood. 2005; 107(2):550-7. DOI: 10.1182/blood-2005-05-2047. View

Aggarwal B, Gupta S, Kim J . Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2011; 119(3):651-65. PMC: 3265196. DOI: 10.1182/blood-2011-04-325225. View

Sakai N, Wada T . Revisiting inflammation in diabetic nephropathy: the role of the Nlrp3 inflammasome in glomerular resident cells. Kidney Int. 2014; 87(1):12-4. DOI: 10.1038/ki.2014.322. View

Zafar M, Zheng J, Kong W, Ye X, Gou L, Regmi A . The role of vascular endothelial growth factor-B in metabolic homoeostasis: current evidence. Biosci Rep. 2017; 37(4). PMC: 5577206. DOI: 10.1042/BSR20171089. View

Olofsson B, Korpelainen E, Pepper M, Mandriota S, Aase K, Kumar V . Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A. 1998; 95(20):11709-14. PMC: 21705. DOI: 10.1073/pnas.95.20.11709. View

Rai V, Agrawal D . Transcriptomic Analysis Identifies Differentially Expressed Genes Associated with Vascular Cuffing and Chronic Inflammation Mediating Early Thrombosis in Arteriovenous Fistula. Biomedicines. 2022; 10(2). PMC: 8962355. DOI: 10.3390/biomedicines10020433. View

Jiang Z, Lin Y, Clemont A, Feener E, Hein K, Igarashi M . Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 1999; 104(4):447-57. PMC: 408521. DOI: 10.1172/JCI5971. View

Baran P, Nitz R, Grotzinger J, Scheller J, Garbers C . Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling. J Biol Chem. 2013; 288(21):14756-68. PMC: 3663500. DOI: 10.1074/jbc.M113.466169. View

Ware C . Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol. 2005; 23:787-819. DOI: 10.1146/annurev.immunol.23.021704.115719. View

10.

Stepniewska J, Dolegowska B, Golembiewska E, Marchelek-Mysliwiec M, Domanski M, Ciechanowski K . The activation of complement system in different types of renal replacement therapy. J Physiol Pharmacol. 2020; 71(2). DOI: 10.26402/jpp.2020.2.12. View

11.

Kokubo K, Kurihara Y, Kobayashi K, Tsukao H, Kobayashi H . Evaluation of the Biocompatibility of Dialysis Membranes. Blood Purif. 2015; 40(4):293-7. DOI: 10.1159/000441576. View

12.

Monardo P, Lacquaniti A, Campo S, Bucca M, Casuscelli di Tocco T, Rovito S . Updates on hemodialysis techniques with a common denominator: The personalization of the dialytic therapy. Semin Dial. 2021; 34(3):183-195. DOI: 10.1111/sdi.12956. View

13.

Canaud B, Kooman J, Selby N, Taal M, Francis S, Maierhofer A . Dialysis-Induced Cardiovascular and Multiorgan Morbidity. Kidney Int Rep. 2020; 5(11):1856-1869. PMC: 7609914. DOI: 10.1016/j.ekir.2020.08.031. View

14.

Melchior P, Erlenkotter A, Zawada A, Delinski D, Schall C, Stauss-Grabo M . Complement activation by dialysis membranes and its association with secondary membrane formation and surface charge. Artif Organs. 2020; 45(7):770-778. DOI: 10.1111/aor.13887. View

15.

Kim K, Chung B, Jeon E, Kim B, Choi B, Park C . B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med. 2012; 44(8):465-72. PMC: 3429810. DOI: 10.3858/emm.2012.44.8.053. View

16.

Aggarwal B, Eessalu T, Hass P . Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature. 1985; 318(6047):665-7. DOI: 10.1038/318665a0. View

17.

Meijers R, Litjens N, de Wit E, Langerak A, van der Spek A, Baan C . Uremia causes premature ageing of the T cell compartment in end-stage renal disease patients. Immun Ageing. 2012; 9(1):19. PMC: 3482595. DOI: 10.1186/1742-4933-9-19. View

18.

Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch A . VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A. 2009; 106(15):6152-7. PMC: 2669337. DOI: 10.1073/pnas.0813061106. View

19.

Muller M, Peglau L, Moon L, Gross S, Schulze J, Ruhnau J . Neurotrophin-3 attenuates human peripheral blood T cell and monocyte activation status and cytokine production post stroke. Exp Neurol. 2021; 347:113901. DOI: 10.1016/j.expneurol.2021.113901. View

20.

Kon V, Shelton E, Pitzer A, Yang H, Kirabo A . Inflammation, Lymphatics, and Cardiovascular Disease: Amplification by Chronic Kidney Disease. Curr Hypertens Rep. 2022; 24(10):455-463. PMC: 9615424. DOI: 10.1007/s11906-022-01206-4. View